Autres langues EyePoint Pharmaceuticals, Inc.

Actions

EYPT

US30233G2093

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
17,63 ^USD	+5,25%		+4,01%	-23,71%

02/04	EyePoint Pharmaceuticals, Inc. élargit son conseil scientifique consultatif	CI
07/03	Mise à jour sectorielle : Les actions du secteur de la santé sont mitigées avant la cloche jeudi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	17/04
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	16/04
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists	02/04
EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	02/04
EyePoint Pharmaceuticals : Investor Presentation March 2024	22/03
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	18/03
EyePoint Pharmaceuticals, Inc.(NasdaqGM:EYPT) added to S&P Pharmaceuticals Select Industry Index	18/03
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	07/03
EyePoint Pharmaceuticals' Q4 Net Loss Narrows, Revenue Advances; Shares Up Pre-Bell	07/03
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q4 Revenue $14M	07/03
EyePoint Pharmaceuticals: Q4 Earnings Snapshot	07/03
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
EyePoint Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
North American Morning Briefing : Powell Still in -2-	07/03
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	04/03
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer	04/03
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	04/03
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024	29/02
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues EyePoint Pharmaceuticals, Inc.

Actions

EYPT

US30233G2093

Autres langues

Filtres